Diabetes
Refine Search
Pharmaceutical
Danish healthcare company Novo Nordisk has pledged $20 million towards the fight against urban diabetes following pioneering research by University College London. 16 November 2015
Pharmaceutical
A national disease awareness program is critical to ensuring the widest population benefits from the value of innovative medicines in diabetes, according to a new report from consulting firm Charles River Associates. 12 November 2015
Pharmaceutical
New findings from a health economics and outcomes research (HEOR) analysis demonstrated that Victoza (liraglutide) 1.2mg is cost-effective for the treatment of type 2 diabetes in the UK market when compared to lixisenatide and is cost-saving compared to exenatide.. 10 November 2015
Pharmaceutical
Korea-based pharmaceutical company Hanmi Pharmaceuticals has entered into an exclusive license agreement with Janssen Pharmaceuticals. 10 November 2015
Pharmaceutical
Chugai Pharmaceutical and privately-held Kowa Company have agreed to expand the license agreement to include the USA and European Union for Chugai’s original selective SGLT2 inhibitor. 9 November 2015
Pharmaceutical
French drug major Sanofi on Friday said it has signed a collaboration and license agreement with Lexicon Pharmaceuticals worth an upfront payment of $300 million to develop and market sotagliflozin, a drug candidate to treat diabetes. 6 November 2015
Pharmaceutical
French pharma major Sanofi has entered into a worldwide license agreement with South Korea’s Hanmi Pharmaceutical to develop a portfolio of experimental, long-acting diabetes treatments. 5 November 2015
Pharmaceutical
Germany’s Merck KGaA on Tuesday said the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated labelling for Glucophage XR (extended release metformin) for type 2 diabetes patients with moderate renal impairment stage or stable chronic heart failure. 3 November 2015
Pharmaceutical
Sales for the first nine months of 2015 at Danish diabetes care giant Novo Nordisk increased by 23% in Danish kroner and by 9% in local currencies to 79.1 billion kroner ($11.7 billion), the company reported this morning. 29 October 2015
Pharmaceutical
Germany’s Merck KGaA has signed an agreement with Nanolek, one of Russia’s largest drugmakers, on the establishment of production of its drugs at the facilities of Nanolek in the Kirov region of Russia, according to an official spokesman of the Kirov government. 22 October 2015
Pharmaceutical
Chinese drugmaker Yabao Pharmaceutical has entered into a second strategic collaboration for the treatment of diabetes with US pharma major Eli Lilly to co-develop Lilly's sodium-glucose linked transporter inhibitor (SGLT1) molecule. 21 October 2015
Pharmaceutical
The US Food and Drug Administration has issued a complete response letter (CRL) regarding Anglo-Swedish pharma company AstraZeneca’s New Drug Application for the investigational fixed-dose combination of saxagliptin and dapagliflozin for the treatment of adult patients with type 2 diabetes. 16 October 2015
Pharmaceutical
Emisphere Technologies has entered into a development and license agreement with Novo Nordisk to develop and commercialize oral formulations of four classes of the Danish diabetes care giant’s investigational molecules. 15 October 2015
Pharmaceutical
Indian pharma company Lupin and German family-owned drugmaker Boehringer Ingelheim are to forge a joint strategic alliance for co-marketing linagliptin in India. 14 October 2015
Pharmaceutical
Biodel says that the US Food and Drug Administration has removed the partial clinical hold for Biodel's previously initiated Phase IIb Study 3-250, a randomized, open-label, parallel group study in patients with insulin-treated type 2 diabetes comparing the use of BIOD-531 to Humalog (insulin lispro) Mix 75/25. 13 October 2015
Pharmaceutical
The Scottish Medicines Consortium (SMC) has made decisions on three products. 12 October 2015
Pharmaceutical
Eli Lilly has acquired worldwide rights to Canadian firm Locemia Solutions’ intranasal glucagon, a potential treatment for severe hypoglycemia in people with diabetes treated with insulin. 10 October 2015
Generics
An Indian court has banned Indian pharma company Glenmark from selling generics of Januvia (sitagliptin) from Merck & Co. 8 October 2015
Generics
The US Food and Drug Administration has approved US generics drugmaker Impax Laboratories’ generic version of diabetes drug glyburides, marketed as Diabeta by France’s Sanofi. 5 October 2015
Pharmaceutical
Danish insulin giant Novo Nordisk has appointed Stephen Gough as senior principal clinical scientist. 30 September 2015
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze